Jefferies Financial Group’s Travere Therapeutics TVTX Stock Holding History

Jefferies Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Buy	29,037 +24,200	+500%	+$1.07M	0.01%	758
2026 Q1	$144K	Buy	4,837 +1,837	+61%	+$54.9K	﹤0.01%	1564
2025 Q4	$115K	Sell	3,000 -1,000	-25%	-$32.5K	﹤0.01%	1690
2025 Q3	$95.6K	Buy	+4,000	New	+$75.2K	﹤0.01%	1345
2024 Q3	–	Sell	-59,300	Closed	-$487K	–	1777
2024 Q2	$487K	Hold	59,300	–	–	0.01%	979
2024 Q1	$457K	Buy	+59,300	New	+$500K	﹤0.01%	1088
2023 Q2	–	Sell	-15,000	Closed	-$337K	–	2010
2023 Q1	$337K	Buy	+15,000	New	+$319K	﹤0.01%	1200

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's TVTX Position: Q2 2026 in Review

Jefferies Financial Group increased its Travere Therapeutics (TVTX) stake by 500% in Q2 2026, buying an estimated $1.07M and bringing the position to 29,037 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #758.

Jefferies Financial Group first reported a position in TVTX in Q1 2023 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Jefferies Financial Group held 29,037 shares of Travere Therapeutics worth $1.65M as of Q2 2026.
Jefferies Financial Group bought 24,200 Travere Therapeutics shares in Q2 2026, an estimated $1.07M.
Travere Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #758 holding.
Jefferies Financial Group first reported a position in Travere Therapeutics in Q1 2023 and has held it in 7 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.